Peptic ulcer disease today (Q28194844)

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

The burden of selected digestive diseases in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

Update on the immunologic basis of Helicobacter pylori gastritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

The physiology of gastric acid secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

Effect of age on the frequency of active Campylobacter pylori infection diagnosed by the [13C]urea breath test in normal subjects and patients with peptic ulcer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

Endoscopy in asymptomatic minidose aspirin consumers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin--analysis of gastrointestinal bleeding during the UK-TIA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

American gastroenterological association technical review on the evaluation of dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

Helicobacter pylori "test and treat" or endoscopy for managing dyspepsia: an individual patient data meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

Stool antigen assay (HpSA) is less reliable than urea breath test for post-treatment diagnosis of Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

Helicobacter pylori antibiotic resistance: trends over time

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

Is it time for quadruple therapy to be first line?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

Helicobacter pylori eradication as the sole treatment for gastric and duodenal ulcers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

Systematic review and meta-analysis: is 1-week proton pump inhibitor-based triple therapy sufficient to heal peptic ulcer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

New data on healing of nonsteroidal anti-inflammatory drug-associated ulcers and erosions. Omeprazole NSAID Steering Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

Economic analysis of strategies in the prevention of non-steroidal anti-inflammatory drug-induced complications in the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

Recommendations for the appropriate use of anti-inflammatory drugs in the era of the coxibs: defining the role of gastroprotective agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

The gastrointestinal tolerability of the LOX/COX inhibitor, licofelone, is similar to placebo and superior to naproxen therapy in healthy volunteers: results from a randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

Helicobacter pylori and NSAIDs--the end of the debate?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

Effect of Helicobacter pylori eradication on anti-thrombotic dose aspirin-induced gastroduodenal mucosal injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

Management of peptic ulcer disease not related to Helicobacter pylori or NSAIDs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

What is the role of Helicobacter pylori in peptic ulcer and gastric cancer outside the big cities?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

Systematic review and meta-analysis of proton pump inhibitor therapy in peptic ulcer bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

Risk factors associated with refractory peptic ulcers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

Duodenal ulcer promoting gene of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

NSAID-induced peptic ulcers and Helicobacter pylori infection: implications for patient management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

Geographic and temporal variations in the occurrence of peptic ulcer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

7 January 2021

The prevalence of self-reported peptic ulcer in the United States

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

7 January 2021

Pathogenesis of duodenal ulcer disease: the rest of the story

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

7 January 2021

Nonsteroidal anti-inflammatory drug gastropathy

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

7 January 2021

Reduction of peptic ulcer disease and Helicobacter pylori infection but increase of reflux esophagitis in Western Sydney between 1990 and 1998

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

7 January 2021

Clinical trends in ulcer diagnosis in a population with high prevalence of Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

7 January 2021

Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

7 January 2021

The influence of isolated doses of drugs, feeding and colonic bacterial ureolysis on urea breath test results

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

7 January 2021

The CLO test in the UK: inappropriate reading and missed results

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

7 January 2021

A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

7 January 2021

Review article: should NSAID/low-dose aspirin takers be tested routinely for H. pylori infection and treated if positive? Implications for primary risk of ulcer and ulcer relapse after initial healing

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

7 January 2021

Non-Helicobacter pylori and non-NSAID peptic ulcer disease in the Japanese population

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0393

7 January 2021